SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Escalating Middle East shipping and energy-infrastructure threats are driving crude-oil supply concerns and attention to USO. Traders are split between expecting further gains if disruptions persist and anticipating a pullback if diplomacy or additional supply eases the risks; many also worry that elevated oil prices could pressure equities and inflation.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO slide and fresh lows are driving discussion, with traders pointing to continued lockup-related share supply and insider selling, as well as a TD Cowen price-target cut and concerns about growth and customer concentration. Bearish traders expect more pressure, while some bullish holders view the decline as an oversold buying opportunity and argue the companys AI-chip technology has long-term potential.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves debt-heavy expansion and rising financing costs are driving concern, amplified by HSBCs warning that slower AI demand could pressure growth. Traders are sharply divided: bears focus on refinancing risk, insider selling and the weak share price, while bulls point to contracted demand and recent analyst support.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a broad neocloud selloff as traders question whether AI infrastructure spending will earn adequate returns and how providers will finance expansion, with CoreWeaves debt concerns adding to fears of sector contagion. The community is split between viewing the recent rebound as an oversold buying opportunityciting Nebiuss comparatively stronger balance sheetand expecting further declines amid funding and cash-flow concerns.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A volatile tech-led rebound following an AI-stock selloff has QQQ traders debating whether dip-buying marks a recovery or a temporary bounce, with concerns about AI infrastructure spending and debt weighing against optimism ahead of major tech earnings. Rising oil prices add to macro unease, while many traders focus on whether the rebound can hold.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

UBSs downgrade of NuScale and cut to its price target have intensified selling, with traders focused on delayed project timelines, a lack of firm customer commitments, and cash-burn concerns. The community is divided between viewing the selloff as an opportunity and seeing it as evidence of execution risk, amid broader weakness in nuclear stocks.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicors Q3 report is driving attention: revenue beat expectations, while GAAP EPS fell short of some estimates and traders noted the lack of forward guidance. Reactions are mixed, with some focusing on strong growth and royalty revenue, while others question whether the results and outlook justify the stocks reaction.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs quarterly earnings beat expectations and the company announced a new share-repurchase authorization, but shares fell as traders focused on a narrowed full-year profit outlook without a higher midpoint. The reaction reflects a split between optimism over capital returns and stronger cash-flow expectations and concern that cautious guidance outweighed the earnings beat.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospace is drawing attention after a third-quarter earnings beat and an increase to its 2026 outlook. Traders largely praised the report but questioned the stocks decline, debating whether it reflects profit-taking or broader market weakness.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTX is drawing attention after reporting a strong third-quarter earnings beat and raising its full-year outlook, with traders highlighting strength across its aerospace and defense businesses. The reaction is broadly upbeat, though some question how much of the guidance increase reflects IEEPA cost recoveries rather than underlying growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pfizers climb toward a new 52-week high is drawing attention, with traders citing defensive-sector rotation and pipeline progress, including upcoming IDWeek presentations, as possible support. Bulls see momentum building, while skeptics point to repeated resistance near a major round-number level and question whether the rally has a durable catalyst.

SLS Stock Jumps Overnight: Retail Eyes Huge Potential Buyout As CEO Marks 15 Years 

Equity

Executive severance changes from June and Sellas’ sizable ASH conference booth have fueled deal speculation.

Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally?

Key PointsA rotation may be taking place, out of tech stocks and into healthcare...

Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch

Pfizer's Q3 results will shed light on its non-oncology portfolio, as demand trends, pricing pressure and vaccine sales shape performance across key therapies.

Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?

CORT banks on newly approved drug, Lifyorli, while potential new approvals and clinical studies could help diversify revenues beyond Korlym.

Warren Buffett's Market Warning Is Hard to Ignore. But I'd Buy These 3 Stocks Anyway.

Key PointsPharmaceutical giant Pfizer is in the midst of a transition that's moving faster than most investors might think...

Nurse Deemed 'Not Disabled Enough' For Payout After COVID Jab Paralysis

Nurse Deemed 'Not Disabled Enough' For Payout After COVID Jab Paralysis

 Authored by Steve Watson via Modernity.news,

An NHS nurse in the UK has been denied compensation despite being permanently damaged by a COVID vaccine during a trial.

Marie-Claire Hoyle, who volunteered for the...

Stocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over Buyouts

Deals for AI discovery platforms and differentiated experimental candidates for obesity and solid tumors dominated the week.


Pfizer, Thermo Fisher Scientific And More: CNBC's 'Final Trades'

CNBC Final Trades: Weiss picked 10-year Treasuries, Thomas chose XAR, Firestone favored TMO, and Terranova selected PFE.read more...

Why Did GME, BMBL, PFE Stocks Hit 52-Week Highs Today? 

Insider purchases, a multibillion-dollar acquisition and progress in vaccine research helped drive interest.


Pfizer (PFE) Gains As Market Dips: What You Should Know

The latest trading day saw Pfizer (PFE) settling at $29.21, representing a +2.96% change from its previous close.

This account has been verified as an official PFE representative.

Verified Account

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Bullish Sentiment

<ul class="summary-bullets"><li>CEO Angelos Stergiou marked Sellas’ 15th anniversary, pointing to its “next chapter” with GPS and SLS009.</li><li>Retail investors floated $40 billion-$120 billion valuation scenarios and share-price predictions ranging from $100 to $540.&nbsp;</li><li>Investors await Regal’s final-analysis trigger of 80 deaths, following Sellas’ disclosure of 78 events as of May 11.</li></ul>Retail investors in Sellas Life Sciences (SLS) are floating multibillion-dollar buyout scenarios and steep share-price gains after CEO Angelos Stergiou marked the company’s 15th anniversary with a post about its “next chapter.”<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> jumped 5% on Monday to $10.49, snapping three straight losing sessions.&nbsp;<h2 class="st-heading-2">Sellas CEO Points To ‘Best Chapters’ Ahead</h2>In his LinkedIn post, Stergiou reflected on Sellas’ growth from a private startup into a public biotech advancing investigational cancer treatments GPS and SLS009.“Reaching 15 years isn't just about celebrating our history; it is about stepping into our next chapter with even greater focus, drive, and resolve,” he said. He acknowledged past setbacks and thanked shareholders, employees and trial participants, while reaffirming the company’s commitment to patients.“Our mission remains deeply personal, and our promise to the patients we aim to serve is steadfast. We look forward, God willing, to the best chapters that are still to be written with GPS and SLS009,” he added.<h2 class="st-heading-2">SLS Retail Floats Multibillion-Dollar Buyout Scenarios</h2>On Stocktwits, retail sentiment for SLS slipped to ‘bearish’ from ‘bullish’ levels a day ago amid a 258% jump in 24-hour message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_725c1f1d42.png" alt="sls ss.png" width="633" height="343"><figcaption>SLS sentiment and message volume as of October 19 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Reformed_MMAT_investor/message/666881029">said</a>: “My opinion, Dr. Stergiou’s message was a master-class at reassuring EVERYONE that all is well.”A user<a href="https://stocktwits.com/Gebinator/message/666869438"> also&nbsp;floated</a> a minimum $40 billion valuation. Another user<a href="https://stocktwits.com/55X_ROI_Q1_2026/message/666882686">&nbsp;argued</a> for a $50 billion valuation, calling a $247-per-share figure. A separate user<a href="https://stocktwits.com/vlucky16/message/666866929">&nbsp;proposed</a> a $120 billion buyout scenario and also predicted a share price of $540-plus.Across bullish share-price predictions, including scenarios tied to clinical results, targets ranged from $100 to over $540. Discussing buyout news in case of favorable data, one user&nbsp;<a href="https://stocktwits.com/AIALuckyDog/message/666879536">said</a>: “If BO news post good data then there’s no stopping this beast (really no explanation required as it could go full berserker mode).” BO means buyout.Another user challenged the lofty valuations and&nbsp;<a href="https://stocktwits.com/noviceEve/message/666855368">said</a>: “I will be so glad to get out of this ticker when it hits $15 again.”<h2 class="st-heading-2">Retail Searches Filings, Conference Plans For Clues</h2>The CEO’s message comes as investors have been&nbsp;searching for potential deal signals in recent months. In June, a filing disclosed changes to executive severance arrangements, including lump-sum payment provisions for Stergiou.For CFO John Burns and chief development officer Dragan Cicic, qualifying departures within one month before or one year after a change of control would trigger 15 months of salary, the annual target bonus, up to 18 months of health-coverage reimbursements and full vesting of unvested equity.&nbsp;Sellas’ conference plans have provided another talking point. The company is listed at Booth 138, with a 20-by-30-foot space, for the Dec.12- Dec.15 American Society of Hematology (ASH) meeting in New Orleans. Major exhibitors include Eli Lilly, Pfizer, Merck, AbbVie and Bristol Myers Squibb. The booth size has fueled speculation about a partnership or acquisition.<h2 class="st-heading-2">Sellas Regal Trial And SLS009 Data In Focus</h2>Currently, investors are awaiting data from Sellas’ two lead programs. The Phase 3 Regal trial is testing GPS, an immunotherapy targeting WT1, in acute myeloid leukemia (AML) patients who achieved a second complete remission following salvage treatment. Its final-analysis process is triggered by 80 deaths. Sellas reported 78 events as of May 11. Reaching 80 precedes database lock, data review and analysis before results are disclosed.&nbsp;The company also expects fourth-quarter topline data from its 80-patient Phase 2 SLS009 study in newly diagnosed AML, including patients with early resistance to azacitidine and venetoclax. SLS009 is also being explored in pancreatic cancer. Preclinical findings from last month showed 17.9% apoptosis (programmed cell death) in a patient-derived tumor model resistant to Daraxonrasib, versus 2.8% with Daraxonrasib alone. Combining the drugs raised apoptosis to 36.5% and necrosis to 30.6%.&nbsp;SLS stock has surged 178% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/avgo-stock-10-year-docomo-deal-retail-on-edge-ceo-ai-casino-remarks/cZxqiudRBuJ">AVGO Stock Edges Up Overnight After 10-Year Docomo Deal, But Retail Stays On Edge Over CEO’s AI ‘Casino’ Remarks&nbsp;</a>

Representative Image (Photo credit: Getty Images)

SLS Stock Jumps Overnight: Retail Eyes Huge Potential Buyout As CEO Marks 15 Years

Abbvie Inc

Bristol-Myers Squibb Co.

Lilly(Eli) & Co

Merck & Co Inc

Pfizer Inc

SELLAS Life Sciences Group Inc

SPDR S&P Biotech ETF

Track PFE stock price, charts, news and real-time market activity on Stocktwits. Join the PFE message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Pfizer Inc stock.

PFE Stock Price Today - Pfizer Inc News, Charts, Retail Sentiment

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$29.44
Prev Close	$29.58
Open	$29.31
Dividend Yield	6.91%
50-Day Moving Average	$28.02
Beta	0.35
Avg. Volume	32.9M
PE Ratio	38.98

52-Week High	$29.88
52-Week Low	$23.62
Market Capitalization	$168.6B
EPS (Annual)	$1.36
Price to Book	1.97
Revenue Per Employee	$834,386.67

Feed

News

Sentiment

Earnings

NewFutures

Fundamentals

Info

PFE Fundamentals